November 29, 2022

Login to your account

Username *
Password *
Remember Me

Create an account

Fields marked with an asterisk (*) are required.
Name *
Username *
Password *
Verify password *
Email *
Verify email *
Captcha *
Reload Captcha

Pre IPO

adada-300x161

By Renaissance Capital,

Bellevue Life Sciences Acquisition, a blank check company backed by Bellevue Capital Management targeting the biotech sector, filed on Friday with the SEC to raise up to $60 million in an initial public offering.

The Bellevue, WA-based company plans to raise $60 million by offering 6 million units at $10. Each unit consists of one share of common stock and one warrant, exercisable at $11.50. At the proposed deal size, Bellevue Life Sciences Acquisition would command a market value of $79 million.

The company is led by CEO and Director Peter Hwang, the founder and Managing Partner of Bellevue Capital Management, and Chairman Steven Reed, the founder and CEO of immunotherapy...

Week_Ahead-300x173

By Renaissance Capital,

In what would be the second largest IPO of the year, eyecare company Bausch + Lomb (BLCO) is scheduled to debut in the week ahead. Some small issuers and...

BLCO_logo

By Renaissance Capital,

Bausch + Lomb, a leading supplier of contact lenses and eyecare products, announced terms for its IPO on Thursday. The company plans to dual list on the Toronto Stock...

Page 1 of 38

© 2021 Disruptive Fare @ DisruptiveFare.com a production of Crediblock.com LLC

Please publish modules in offcanvas position.